This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiang, J. Articles by Roman, R. J. Search for Related Content PubMed PubMed Citation Articles by Jiang, J. Articles by Roman, R. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB HYDRALAZINE HYDROCHLORIDE LOVASTATIN

(Hypertension. 1997;30:968-974.)
© 1997 American Heart Association, Inc.

Articles

Lovastatin Prevents Development of Hypertension in Spontaneously Hypertensive Rats

Jian Jiang; ; Richard J. Roman

From the Department of Physiology, Medical College of Wisconsin, Milwaukee.

Correspondence to Richard J. Roman, PhD, Department of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226.

Abstract The present study evaluated the effects of lovastatin on renal function and the development of hypertension in spontaneously hypertensive rats (SHR). Four-week-old SHR were given lovastatin (10 mg/kg) or vehicle twice daily by gavage. After 4 weeks of treatment, mean arterial pressure was significantly lower in lovastatin-treated SHR (131±4 mm Hg, n=5) than in control animals (160±4 mm Hg, n=12) (P<.05). The fall in arterial pressure in lovastatin-treated rats was accompanied by changes in renal function. The slope of the relationship between arterial pressure and sodium excretion was threefold greater in lovastatin-treated SHR (n=6) than in control rats (n=6), and this was associated with significant elevations in renal medullary blood flow and renal interstitial hydrostatic pressure. Glomerular filtration rate was 17% higher in lovastatin-treated SHR (n=6) than in control rats (n=6) (0.94±0.05 versus 0.81±0.07 mL/min per g of kidney weight, P<.05). The wall-to-lumen area ratio of renal arterioles was significantly reduced in lovastatin-treated SHR compared with vehicle-treated rats (0.86±0.05 versus 1.08±0.04 for vessels with inner diameters <50 µm and 0.62±0.02 versus 0.75±0.04 for vessels with inner diameters of 50 to 100 µm, P<.05). These results indicate that chronic treatment with lovastatin shifts the relations between renal medullary blood flow, renal interstitial pressure, sodium excretion, and renal perfusion pressure to lower levels of arterial pressure and attenuates the development of hypertension and renal vascular hypertrophy in SHR.

Key Words: lovastatin • hypertension • rats, inbred SHR • natriuresis • hypertrophy

This article has been cited by other articles:

				L. Paulsen, C. Holm, J. N. Bech, J. Starklint, and E. B. Pedersen Effects of statins on renal sodium and water handling: Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1556 - 1561. [Abstract] [Full Text] [PDF]

				S. Mangat, S. Agarwal, and C. Rosendorff Do Statins Lower Blood Pressure? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 112 - 123. [Abstract] [PDF]

				M. Varela and J. L. Garvin Acute and Chronic Regulation of Thick Ascending Limb Endothelial Nitric Oxide Synthase by Statins J. Am. Soc. Nephrol., February 1, 2004; 15(2): 269 - 275. [Abstract] [Full Text] [PDF]

				S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress Hypertension, August 1, 2002; 40(2): 142 - 147. [Abstract] [Full Text] [PDF]

				M. A. van Dijk, A. M. Kamper, S. van Veen, J. H. M. Souverijn, and G. J. Blauw Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2152 - 2157. [Abstract] [Full Text] [PDF]

				O. Regrigny, J. Atkinson, C. Capdeville-Atkinson, P. Liminana, and J.-M. Chillon Effect of Lovastatin on Cerebral Circulation in Spontaneously Hypertensive Rats Hypertension, May 1, 2000; 35(5): 1105 - 1110. [Abstract] [Full Text] [PDF]

				N. Glorioso, C. Troffa, F. Filigheddu, F. Dettori, A. Soro, P. P. Parpaglia, S. Collatina, and M. Pahor Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential Hypertension and Primary Hypercholesterolemia Hypertension, December 1, 1999; 34(6): 1281 - 1286. [Abstract] [Full Text] [PDF]

				A. Faggiotto and R. Paoletti Statins and Blockers of the Renin-Angiotensin System : Vascular Protection Beyond Their Primary Mode of Action Hypertension, October 1, 1999; 34(4): 987 - 996. [Abstract] [Full Text] [PDF]

				V. GROSS, W. SCHNEIDER, W.-H. SCHUNCK, E. MERVAALA, and F. C. LUFT Chronic Effects of Lovastatin and Bezafibrate on Cortical and Medullary Hemodynamics in Deoxycorticosterone Acetate-Salt Hypertensive Mice J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1430 - 1439. [Abstract] [Full Text]

				P. Nazzaro, M. Manzari, M. Merlo, R. Triggiani, A. Scarano, L. Ciancio, and A. Pirrelli Distinct and Combined Vascular Effects of ACE Blockade and HMG-CoA Reductase Inhibition in Hypertensive Subjects Hypertension, February 1, 1999; 33(2): 719 - 725. [Abstract] [Full Text] [PDF]

				T. W. Wilson, M. Alonso-Galicia, and R. J. Roman Effects of Lipid-Lowering Agents in the Dahl Salt-Sensitive Rat Hypertension, January 1, 1998; 31(1): 225 - 231. [Abstract] [Full Text] [PDF]